Effectiveness of Polyvalent Bacterial Lysate and Autovaccines Against Upper Respiratory Tract Bacterial Colonization by Potential Pathogens: A Randomized Study

Olaf Zagólski, Paweł Stręk, Andrzej Kasprowicz, Anna Białecka, Olaf Zagólski, Paweł Stręk, Andrzej Kasprowicz, Anna Białecka

Abstract

Background: Polyvalent bacterial lysate (PBL) is an oral immunostimulating vaccine consisting of bacterial standardized lysates obtained by lysis of different strains of bacteria. Autovaccines are individually prepared based on the results of smears obtained from the patient. Both types of vaccine can be used to treat an ongoing chronic infection. This study sought to determine which method is more effective against nasal colonization by potential respiratory tract pathogens.

Material and methods: We enrolled 150 patients with aerobic Gram stain culture and count results indicating bacterial colonization of the nose and/or throat by potential pathogens. The participants were randomly assigned to each of the following groups: 1. administration of PBL, 2. administration of autovaccine, and 3. no intervention (controls).

Results: Reduction of the bacterial count in Streptococcus pneumoniae-colonized participants was significant after the autovaccine (p<0.001) and PBL (p<0.01). Reduction of the bacterial count of other β-hemolytic streptococcal strains after treatment with the autovaccine was significant (p<0.01) and was non-significant after PBL. In Haemophilus influenzae colonization, significant reduction in the bacterial count was noted in the PBL group (p<0.01). Methicillin-resistant Staphylococcus aureus colonization did not respond to either treatment.

Conclusions: The autovaccine is more effective than PBL for reducing bacterial count of Streptococcus pneumoniae and β-hemolytic streptococci, while PBL was more effective against Haemophilus influenzae colonization.

References

    1. Anon JB. Upper respiratory infections. Am J Med. 2010;123:S16–25.
    1. Dhakal R, Sujatha S, Parija SC, Bhat BV. Asymptomatic colonization of upper respiratory tract by potential bacterial pathogens. Indian J Pediatr. 2010;77:775–78.
    1. Lanzilli G, Falchetti R, Tricarico M, et al. In vitro effects of an immunostimulating bacterial lysate on human lymphocyte function. Int J Immunopathol Pharmacol. 2005;18:245–54.
    1. Jareoncharsri P, Bunnag C, Tunsuriyawong P, et al. An open-label, prospective study of an oral polyvalent bacterial lysate (Luivac) in the treatment of recurrent respiratory tract infections in Thai patients. Asian Pac J Allergy Immuno. 2003;21:223–30.
    1. Lanzilli G, Falchetti R, Cottarelli A, et al. In vivo effect of an immunostimulating bacterial lysate on human B lymphocytes. Int J Immunopathol Pharmaco. 2006;19:551–59.
    1. Rosaschino F, Cattaneo L. Strategies for optimizing compliance of paediatric patients for seasonal antibacterial vaccination with sublingually administered Polyvalent Mechanical Bacterial Lysates (PMBL) Acta Biome. 2004;75:171–78.
    1. Faure GC, Béné MC, Simon C, Quantain A. Increase in specific antibody-forming cells in human tonsils after oral stimulation with D-53, a ribosomal vaccine. Int J Immunopharmaco. 1990;12:315–20.
    1. Han L, Zheng CP, Sun YQ, et al. A bacterial extract of OM-85 Broncho-Vaxom prevents allergic rhinitis in mice. Am J Rhinol Allergy. 2014;28:110–16.
    1. Bitar MA, Saade R. The role of OM-85 BV (Broncho-Vaxom) in preventing recurrent acute tonsillitis in children. Int J Pediatr Otorhinolaryngol. 2013;77:670–73.
    1. Ricci R, Palmero C, Bazurro G, et al. The administration of a polyvalent mechanical bacterial lysate in elderly patients with COPD results in serological signs of an efficient immune response associated with a reduced number of acute episodes. Pulm Pharmacol Ther. 2014;27:109–13.
    1. Cazzola M, Anapurapu S, Page CP. Polyvalent mechanical bacterial lysate for the prevention of recurrent respiratory infections: a meta-analysis. Pulm Pharmacol Ther. 2012;25:62–68.
    1. Guaní-Guerra E, Negrete-García MC, Montes-Vizuet R, et al. Human b-defensin-2 induction in nasal mucosa after administration of bacterial lysates. Arch Med Res. 2011;42:189–94.
    1. Béné MC, Kahl L, Perruchet AM, et al. Bacterial lysates and ribosomes as inducers of specific immune responses: a comparative study. Scand J Immuno. 1993;38:496–98.
    1. Zanin C, Béné MC, Perruchet AM, et al. Bacterial crude extracts or ribosomes are recognized similarly by peripheral and mucosal B cells. FEMS Immunol Med Microbio. 1994;10:11–18.
    1. Rizzo C, Brancaccio G, De Vito D, Rizzo G. Efficacy of autovaccination therapy on post-coronary artery bypass grafting methicillin-resistant Staphylococcus aureus mediastinitis. Interact Cardiovasc Thorac Sur. 2007;6:228–29.
    1. Volgin AR, Demina IuV. Experience of using bacterial lysate IRS 19 for the prophylaxis of the diseases of respiratory organs in organized groups. Zh Mikrobiol Epidemiol Immunobio. 2005;3:82–84.
    1. Bae S, Yu JY, Lee K, et al. Nasal colonization by four potential respiratory bacteria in healthy children attending kindergarten or elementary school in Seoul, Korea. J Med Microbio. 2012;61:678–85.
    1. Nadel DM, Lanza DC, Kennedy DW. Endoscopically guided sinus cultures in normal subjects. Am J Rhinol. 1999;13:87–90.
    1. Jomrich N, Kellner S, Djukic M, et al. Absence of Streptococcus pneumoniae in pharyngeal swabs of geriatric inpatients. Infect Dis (Lond) 2015;6:1–6.
    1. Tricarico D, Varricchio A, D’Ambrosio S, et al. Prevention of recurrent upper respiratory tract infections in a community of cloistered nuns using a new immunostimulating bacterial lysate. A randomized, double-blind clinical trial. Arzneimittelforschung. 2004;54:57–63.
    1. Cox RA, Conquest C. Strategies for the management of healthcare staff colonized with epidemic methicillin-resistant Staphylococcus aureus. J Hosp Infec. 1997;35:117–27.
    1. Goerke C, Gressinger M, Endler K, et al. High phenotypic diversity in infecting but not in colonizing Staphylococcus aureus populations. Environ Microbio. 2007;9:3134–42.
    1. Libberton B, Coates RE, Brockhurst MA, Horsburgh MJ. Evidence that intraspecific trait variation among nasal bacteria shapes the distribution of Staphylococcus aureus. Infect Immun. 2014;82:3811–15.
    1. Hamdan-Partida A, Sainz-Espuñes T, Bustos-Martínez J. Characterization and persistence of Staphylococcus aureus strains isolated from the anterior nares and throats of healthy carriers in a Mexican community. J Clin Microbio. 2010;48:1701–5.
    1. Puchta A, Verschoor CP, Thurn T, Bowdish DM. Characterization of inflammatory responses during intranasal colonization with Streptococcus pneumoniae. J Vis Exp. 2014;17:e50490.
    1. Wu K, Yao R, Wang H, et al. Mucosal and systemic immunization with a novel attenuated pneumococcal vaccine candidate confer serotype independent protection against Streptococcus pneumoniae in mice. Vaccine. 2014;32:4179–88.
    1. Safdar N, Narans L, Gordon B, Maki DG. Comparison of culture screening methods for detection of nasal carriage of methicillin-resistant Staphylococcus aureus: a prospective study comparing 32 methods. J Clin Microbiol. 2003;41:3163–66.
    1. Lee CS, Montalmont B, O’Hara JA, et al. Screening for methicillin-resistant Staphylococcus aureus colonization using sponges. Infect Control Hosp Epidemiol. 2015;36:28–33.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren